BEONEBIO

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 12 Sept 2024 filing date already counts against anyone who files later.

Record

Serial number

98746793

Mark type

Stylized text

Filed

12 Sept 2024

Published for opposition

09 Sept 2025

Attorney of record

Kristen Ruisi

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
• Class 040 — Treatment of materials: Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
• Class 042 — Scientific and technological services: Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging design
• Class 044 — Medical, beauty and agricultural services: Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advice, namely, pharmaceutical advice

Owner

• BeiGene Switzerland GMBH, Basel, CH
• BeiGene Switzerland GMBH, Basel, CH

Prosecution history

• 04 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 09 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 09 Sept 2025 — PUBLISHED FOR OPPOSITION
• 03 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 08 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 22 Jul 2025 — EXAMINER'S AMENDMENT ENTERED
• 22 Jul 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 22 Jul 2025 — EXAMINERS AMENDMENT E-MAILED
• 22 Jul 2025 — EXAMINERS AMENDMENT -WRITTEN
• 17 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 17 Mar 2025 — NON-FINAL ACTION E-MAILED
• 17 Mar 2025 — NON-FINAL ACTION WRITTEN
• 12 Mar 2025 — ASSIGNED TO EXAMINER
• 24 Jan 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 16 Sept 2024 — TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED